Cesium carbonate → 2,4,4-Trimethyl-7-{2-(2-methyl-pyrrolidin-1-yl)-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-4-yl}-1,2,3,4-tetrahydro-isoquinoline
Reaction equation
Br[C:2]1[CH:11]=[C:10]2[C:5]([C:6]([CH3:14])([CH3:13])[CH2:7][N:8]([CH3:12])[CH2:9]2)=[CH:4][CH:3]=1.CC1(C)C(C)(C)OB(B2OC(C)(C)C(C)(C)O2)O1.CC([O-])=O.[K+].Cl[C:39]1[CH:44]=[C:43]([N:45]2[CH2:50][CH2:49][N:48]([C:51]3[C:56]([C:57]([F:60])([F:59])[F:58])=[CH:55][CH:54]=[CH:53][N:52]=3)[CH2:47][CH2:46]2)[N:42]=[C:41]([N:61]2[CH2:65][CH2:64][CH2:63][CH:62]2[CH3:66])[N:40]=1.C([O-])([O-])=O.[Cs+].[Cs+]>CS(C)=O.C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.[Fe+2].C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1>[CH3:12][N:8]1[CH2:7][C:6]([CH3:14])([CH3:13])[C:5]2[C:10](=[CH:11][C:2]([C:39]3[CH:44]=[C:43]([N:45]4[CH2:50][CH2:49][N:48]([C:51]5[C:56]([C:57]([F:58])([F:59])[F:60])=[CH:55][CH:54]=[CH:53][N:52]=5)[CH2:47][CH2:46]4)[N:42]=[C:41]([N:61]4[CH2:65][CH2:64][CH2:63][CH:62]4[CH3:66])[N:40]=3)=[CH:3][CH:4]=2)[CH2:9]1Participants
Reactant 5
Product 1
Reagents, catalysts & solvents 3
Procedure
To a mixture of 7-bromo-2,4,4-trimethyl-1,2,3,4-tetrahydro-isoquinoline (140 mg, 0.55 mmol), 4,4,5,5,4′,4′,5′,5′-octamethyl-[2,2′]bi[[1,3,2]dioxaborolanyl] (140 mg, 0.55 mmol), DPPF (9 mg, 0.017 mmol), and KOAc (162 mg, 1.65 mmol) in DMSO, add PdCl2(DPPF)-DCM complex (13 mg, 0.0165 mmol). Purge the reaction mixture for 10 minutes with dry N2. Heat the stirring reaction mixture overnight at 80° C. Cool to room temperature. Add 4-chloro-2-(2-methyl-pyrrolidin-1-yl)-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidine (141 mg, 0.33 mmol), Pd(PPh3)4 (19 mg, 0.017 mmol), and Cs2CO3 (162 mg, 0.50 mmol). Heat the stirring reaction mixture overnight at 80° C., cool to room temperature, and partition between water and EtOAc. Dry the solution (Na2SO4), concentrate under reduced pressure. Purify the residue by flash column chromatography eluting with DCM:MeOH (9:1) to afford 2,4,4-trimethyl-7-{2-(2-methyl-pyrrolidin-1-yl)-6-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrimidin-4-yl}-1,2,3,4-tetrahydro-isoquinoline. 1H NMR (400 MHz, CDCl3): δ 1.30 (m, 9H, 3×CH3); 1.68 (m, 1H, CH2CH2); 1.91 (m, 1H, CH2CH2); 2.05 (m, 2H, CH2CH2); 2.40 (s, 2H); 2.43 (s, 3H, NCH3); 3.39 (m, 4H); 3.61 (s, 2H); 3.67 (m, 2H); 3.79 (m, 4H); 4.34 (m, 1H); 6.27 (s, 1H, Ar—H); 7.01 (m, 1H); 7.35 (m, 1H); 7.63 (s, 1H); 7.88 (m, 1H); 7.88 (m, 1H); 8.44 (m, 1H).
Workup
- additionadd PdCl2(DPPF)-DCM complex (13 mg, 0.0165 mmol)
- customPurge the reaction mixture for 10 minutes with dry N2
- temperatureHeat
- customthe stirring reaction mixture overnight at 80° C
- temperatureHeat
- customthe stirring reaction mixture overnight at 80° C.
- temperaturecool to room temperature
- custompartition between water and EtOAc
- dry with materialDry the solution (Na2SO4)
- concentrationconcentrate under reduced pressure
- customPurify the residue by flash column chromatography
- washeluting with DCM:MeOH (9:1)
Sources & evidence
- ORD record
- ord-cb580462258847cdb80bd2a2e332599b
- Source dataset
- uspto-grants-2009_07
- Patent number
- US07566712B2
Reaction notes
Loading…